The behavioural companion for
GLP-1 treatment
GLP-1 receptor agonists are transforming obesity treatment. But medication alone isn't enough — lasting results require behavioural change alongside pharmacotherapy. Evira provides the monitoring, communication, and lifestyle support that makes GLP-1 treatment more effective.
10%
UK PATIENTS ON GLP-1S
0
WEIGHT REGAIN AT 3 YRS
2-4 min
CLINICAL TIME / PATIENT / WK
Weekly
OBJECTIVE WEIGHT FOLLOW-UP
Why Evira alongside GLP-1 medication
10% of children in UK CEW services using Evira are now also receiving GLP-1 medication. Some services make Evira mandatory before starting GLP-1s — to demonstrate commitment and establish behavioural foundations first.
📏
Prove commitment before prescribing
Some HCPs require patients to demonstrate engagement with Evira before starting GLP-1 treatment. Daily measurements provide objective evidence of commitment.
💊
Dosing communication
Dedicated messaging for GLP-1 dosing — titration schedules, side effect reporting, and adjustment discussions. All in-app, all documented, all in one place.
📈
Separate medication from behaviour
With continuous data alongside medication start dates, distinguish the medication effect from behavioural change — informing decisions about continuation or stepping down.
📊
Objective monitoring during medication
Daily measurements provide continuous, objective data on weight response during GLP-1 treatment. See exactly how patients respond — no reliance on clinic weigh-ins months apart.
🔄
Behavioural foundation — no weight regain
GLP-1s reduce appetite — but weight regain after discontinuation is well-documented. The Evira group shows no weight regain at 3 years, in contrast to known rebound effects after medication stops. The Evira Method builds the lifestyle habits needed for sustained results.
⚠️
Side effect monitoring
Patients & families report GLP-1 side effects via messaging. Rapid weight changes trigger alerts. Intervene early if the response is too aggressive or insufficient.
How it works in practice
Whether GLP-1 medication comes before, during, or after starting Evira — the platform adapts to your clinical pathway.
Establish baseline
Patient starts Evira. Daily measurements establish behavioural baseline.
1
Dose communication
In-app messaging for dosing queries, side effects, titration.
4
GLP-1 decision
Clinician reviews Evira data alongside clinical assessment.
2
Monitor response
Dashboard shows weight trend overlaid with medication timeline.
5
Start medication
GLP-1 titration begins. Daily data shows response in real time.
3
Sustain long-term
Behavioural change continues alongside or after medication.
6
Understanding that it is a long-term journey was crucial for us — with Evira, we have received both support and clarity.
Mother of an 8-year-old girl — treated with Evira for 6 months
GLP-1s in paediatric obesity
GLP-1 receptor agonists are increasingly used in paediatric and adult weight management. In UK CEW services using Evira, 10% of children are now on concurrent GLP-1 treatment. As prescribing grows, structured behavioural monitoring alongside medication becomes critical.
Evira is not a substitute for pharmacotherapy — it's the behavioural infrastructure that makes medication more effective and supports sustained outcomes. Three-year data shows no weight regain in the Evira group, in contrast to known rebound effects after medication discontinuation.
A randomised controlled trial testing Evira for adolescents on GLP-1 medication is underway at 5 university clinics in Sweden (H2 2025).